In a single-arm, phase II trial with prospective molecular stratification (Mesothelioma-Stratified Therapy 1 [MiST1]), patients with relapsed cytoplasmic-BAP1-deficient or BRCA1-deficient mesothelioma (pleural or peritoneal or other primary localization), received rucaparib 600 mg twice a day orally, for up to six cycles of 28 days. Here, BAP1 is linked to mesothelioma.